Boston XO (hexafocon A), Boston EO (enflufocon B) and Boston ES (enflufocon A) Rigid Gas Permeable Contact Lenses are indicated for daily wear for the correction of refractive ametropia (myopia, hyperopia, astigmatism, and presbyopia) in aphakic and not aphakic persons with non-diseased eyes. Also, the lenses may be prescribed in otherwise non-diseased eyes that require a rigid contact lens for the management of irregular corneal conditions such as keratoconus, pellucid marginal degeneration, or following penetrating keratoplasty or refractive (e.g. LASIK) surgery. The lenses may be disinfected using a chemical disinfection system only.

Device Description

Boston XO (hexafocon A) is a rigid gas permeable material, composed of siloxanyl fluoromethacrylate copolymer available with or without an ultraviolet absorber.

The Boston XO (hexafocon A), Boston EO (enflufocon B) and Boston ES (enflufocon A) are rigid gas permeable contact lens materials composed of aliphatic fluoroitaconate siloxanyl methacrylate copolymer available with or without an ultraviolet absorber.

AI/ML Overview

Boston XO, Boston EO, and Boston ES Rigid Gas Permeable Contact Lenses are indicated for daily wear for the correction of refractive ametropia (myopia, hyperopia, astigmatism, and presbyopia) in aphakic and non-aphakic persons with non-diseased eyes. Additionally, these lenses may be prescribed for non-diseased eyes requiring a rigid contact lens for managing irregular corneal conditions such as keratoconus, pellucid marginal degeneration, or following penetrating keratoplasty or refractive surgery (e.g., LASIK). Disinfection must be done using a chemical disinfection system only.

The safety and efficacy of these devices were established in prior 510(k) clearances (K000795, K013762, and K053124). For the current submission (K071043), the primary change was the addition of a UV blocker to the BOSTON XO material. Preclinical testing, as required by the "Pre-Market Notification Guidance for Daily Wear Contact Lenses, May 12, 1994," demonstrated the safety of this change. Since BOSTON EO and BOSTON ES already incorporate the same UV blocker, clinical studies were deemed unnecessary.

A table of acceptance criteria and reported device performance cannot be extracted as the provided text refers to "preclinical testing" for the UV blocker addition but does not detail specific acceptance criteria or performance metrics in a tabular format for this aspect, nor does it provide new clinical study data. The original clearances relied on historical data which is not provided in detail.

1. A table of acceptance criteria and the reported device performance:

Specific acceptance criteria and device performance metrics, particularly for the addition of the UV blocker, are not provided in the document in a comparative table format. The submission primarily relies on the safety and efficacy established in previous 510(k) clearances and states that preclinical testing for the UV blocker was performed as required by guidance.

2. Sample size used for the test set and the data provenance:

Sample size: Not applicable for a new clinical test set. The submission states that "Clinical studies for the BOSTON XO... materials have been deemed as not necessary."
Data provenance: Not applicable, as no new clinical studies were conducted for this 510(k) submission. The safety data for the UV blocker was generated through preclinical testing, but the specifics (e.g., country of origin, retrospective/prospective) are not detailed.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

Not applicable, as no new clinical studies were conducted and thus no expert-established ground truth for a new test set was required.

4. Adjudication method (e.g., 2+1, 3+1, none) for the test set:

Not applicable, as no new clinical studies were conducted.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

Not applicable, as this device is a contact lens and not an AI-assisted diagnostic tool.

6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done:

Not applicable, as this device is a contact lens and not an algorithm.

7. The type of ground truth used:

For the original safety and efficacy of the contact lenses (from the predicate devices), the ground truth would have been based on clinical examinations by ophthalmologists/optometrists assessing visual acuity, ocular health, comfort, and adverse events. For the current submission, the ground truth for the safety of the UV blocker was established through preclinical testing (e.g., biocompatibility, toxicology), as evidenced by the mention of "preclinical testing as required in current Pre-Market Notification Guidance for Daily Wear Contact Lenses, May 12, 1994."

8. The sample size for the training set:

Not applicable for this context, as this is a contact lens approval, not an AI model requiring a training set.

9. How the ground truth for the training set was established:

Not applicable for this context.

Summary

{0}------------------------------------------------

K071043

510(K) SUMMARY BOSTON XO (hexafocon A), BOSTON EO (enflufocon B), and BOSTON ES (enflufocon A) Rigid Gas Permeable Contact Lenses for Daily Wear

1. Applicant's Name and Address

Bausch & Lomb, Inc. 1400 North Goodman Street Rochester. NY 14609

1. Contact Person Debra Ketchum Manager,Global Regulatory Affairs Bausch & Lomb, Inc. 1400 North Goodman Street Rochester, NY 14609 (585) 338-8638

3. ldentification of Device

Common Name:	contact lens-rigid gas permeable (hydrophobic)
Trade Name:	Boston XO (hexafocon A), Boston EO(enflufocon B), and Boston ES (enflufocon A)Daily Wear Contact Lens
Classification:	Class II ophthalmic (21CFR 886.5916)
Device classification:	Class II (21 CFR 886.5916)
Pro Code:	HQD

Predicate Devices:

K053124 and K013762: Boston XO (hexafocon A), Boston EO (enflufocon B), Boston ES (enflufocon A)

510(k)	Clearance Date	Device Description
K053124	1/30/2006	Boston XO, Boston EO,Boston ES
K013762	4/3/2002	Boston XO, Boston EO,Boston ES

{1}------------------------------------------------

4. Description of device

Boston XO (hexafocon A) is a rigid gas permeable material, composed of siloxanyl fluoromethacrylate copolymer available with or without an ultraviolet absorber.

Property	BOSTON XO	BOSTON EO	BOSTON ES
Specific Gravity	1.27	1.23	1.22
Refractive Index	1.425	1.429	1.443
Visible LightTransmittance	92% average	92% average	92% average
UV Blocker	UV 49	UV 49	UV 49
Water Content	<1%	<1%	<1%
Wetting Angle	49°	49°	52°
Oxygen	140*	82*	36*
Permeability(Dk)***	100**	58**	18**

The physical and optical properties of the lenses are:

*gas to gas method

**polarographic method (ISO)

***polarographic method (FATT) (x 10-11 (cm202 x cm)/cm² x sec x mmHg)@35°C

Intended use 5.

The Boston XO (hexafocon A), Boston EO (enflufocon B), and Boston ES (enflufocon A) Rigid Gas Permeable Contact Lenses are indicated for the daily wear correction of refractive ametropia (myopia, hyperopia, astigmatism, and presbyopia) in aphakic and not-aphakic persons with non-diseased eyes. Also, the lenses may be prescribed in otherwise non-diseased eyes that require a rigid contact lens for the management of irregular corneal conditions such as keratoconus, pellucid marginal degeneration, or following penetrating keratoplasty or refractive (e.g. LASIK) surgery. The lenses may be disinfected using a chemical disinfection system only.

{2}------------------------------------------------

6. Description of Safety and Substantial Equivalence

The safety and efficacy of the Boston XO (hexafocon A), Boston EO (enflufocon B), and Boston ES (enflufocon A) was demonstrated in original 510(k) Premarket Notifications as follows:

. K000795, cleared May 25, 2000
. K013762, cleared April 3, 2002
K053124, cleared January 30, 2006 .

Safety and efficacy for all subject devices were determined in prior 510(k) clearances. The addition of the UV blocker to the BOSTON XO material has been demonstrated as safe as evidenced by preclinical testing as required in current Pre-Market Notification Guidance for Daily Wear Contact Lenses, May 12, 1994. All three materials will now use the same UV blocker.

7. Clinical data:

Clinical studies for the BOSTON XO (hexafocon A), BOSTON EO (enflufocon B), and BOSTON ES (enflufocon A) materials have been deemed as not necessary in support of their clearance as no new or additional questions of safety or effectiveness have been raised as a result of the change of UV blocker in BOSTON XO (hexafocon A). BOSTON EO (enflufocon B) and BOSTON ES (enflufocon A) already incorporate the same UV blocker.

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle-like symbol with three curved lines representing wings or feathers. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the symbol.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

AUG - 2 2007

Bausch & Lomb, Inc. c/o Debra Ketchum 1400 North Goodman Street Rochester NY 14609-3547

Re: K071043

Trade/Device Name: Boston XO (hexafocon A), Boston EO (enflufocon B), and Boston ES (enflufocon A) Daily Wear Rigid Gas Permeable Contact Lenses Regulation Number: 21 CFR 886.5916 Regulation Name: Rigid gas permeable contact lens Regulatory Class: Class II Product Code: HOD Dated: July 17, 2007 Received: July 18, 2007

Dear Ms. Ketchum:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{4}------------------------------------------------

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours.

M.B. Egelman SimD

Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

INDICATIONS FOR USE STATEMENT

K 071043

Device Name:

510(k) Number (if known):

Boston XO (hexafocon A), Boston EO (enflufocon B), and Boston ES (eflufocon A) Daily Wear Contact Lens

Indication for Use

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use	X	OR	Over-the -counter-use
(Division Sign-Off)
Division of Ophthalmic Ear, Nose and Throat Devises
510(k) Number	K071043

Regulation Number and Section

§ 886.5916 Rigid gas permeable contact lens.

(a)
Identification. A rigid gas permeable contact lens is a device intended to be worn directly against the cornea of the eye to correct vision conditions. The device is made of various materials, such as cellulose acetate butyrate, polyacrylate-silicone, or silicone elastomers, whose main polymer molecules generally do not absorb or attract water.(b)
Classification. (1) Class II if the device is intended for daily wear only.(2) Class III if the device is intended for extended wear.
(c)
Date PMA or notice of completion of a PDP is required. As of May 28, 1976, an approval under section 515 of the act is required before a device described in paragraph (b)(2) of this section may be commercially distributed. See § 886.3.